Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 6/20 | 0.52 |
| ▸ | THRA | P10827 | 4/20 | 0.52 |
| ▸ | TMPRSS4 | Q9NRS4 | 1/20 | 0.45 |
| ▸ | FADS1 | O60427 | 2/20 | 0.42 |
| ▸ | PNLIP | P16233 | 2/20 | 0.40 |
| ▸ | PARG | Q86W56 | 1/20 | 0.39 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6694178 | 0.91 | THRB (0.51) | THRBTHRATMPRSS4FADS1PNLIP | |
| SCHEMBL6693323 | 0.86 | THRB (0.61) | THRBTHRAKMT2A | |
| SCHEMBL6695738 | 0.83 | THRB (0.53) | THRBTHRA | |
| SCHEMBL6692015 | 0.83 | THRB (0.47) | THRBTHRA | |
| SCHEMBL6693202 | 0.80 | THRA (0.54) | THRBTHRA | |
| Methane SCHEMBL6690821 | 0.79 | THRA (0.53) | THRBTHRA | |
| SCHEMBL6695481 | 0.78 | THRA (0.37) | THRBTHRA | |
| SCHEMBL6690382 | 0.78 | THRB (0.60) | THRBTHRAKMT2A | |
| SCHEMBL6700091 | 0.78 | THRB (0.46) | THRBTHRA | |
| SCHEMBL6699450 | 0.78 | THRB (0.39) | THRBTHRAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6747048-B2 | TREATING DISEASES OR DISORDERS ASSOCIATED WITH METABOLISM DYSFUNCTION OR WHICH ARE DEPENDENT UPON THE EXPRESSION OF A T3 REGULATED GENE, | BRISTOL-MYERS SQUIBB COMPANY | 2004-06-08 | — | — | US | disclosed |
| US-20040039028-A1 | Pyridine-based thyroid receptor ligands | BRISTOL-MYERS SQUIBB COMPANY | 2004-02-26 | — | — | US | disclosed |
| WO-2003094845-A2 | PYRIDINE-BASED THYROID RECEPTOR LIGANDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-11-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040039028-A1 | Pyridine-based thyroid receptor ligands | TSHR, THRB, THRA | THRB 2/4885THRA 3/4885TMPRSS4 1814/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.